Latest Business News in Real Time
LITTLE ROCK, Ark., May 17, 2025 (GLOBE NEWSWIRE) — Dillard’s, Inc. (DDS-NYSE) (the “Company” or “Dillard’s”) announced that the Board of Directors declared a cash dividend of $0.25 per share on the Class A and Class B Common Stock of the Company. The dividend is payable August 4, 2025 to shareholders of record as of June 30, 2025.
CONTACT:
Julie J. Guymon, C.P.A.
501-376-5965
[email protected]
NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating:
ACT NOW. The Shareholder Vote is scheduled for June 24, 2025.
Click here for more
https://monteverdelaw.com/case/proassurance-corporation-pra/. It is free and there is no cost or obligation to you.
ACT NOW. The Tender Offer expires on June 13, 2025.
Click here for more
https://monteverdelaw.com/case/kronos-bio-inc-kron/. It is free and there is no cost or obligation to you.
Click here for more
https://monteverdelaw.com/case/american-axle-manufacturing-holdings-inc-axl/. It is free and there is no cost or obligation to you.
Click here for more
https://monteverdelaw.com/case/springworks-therapeutics-inc-swtx/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:
About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No company, director or officer is above the law. If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341
Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
PR Newswire
NEW YORK
, May 17, 2025 /PRNewswire/ —
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline.
So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Sana class action, go to https://rosenlegal.com/submit-form/?case_id=37267 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (2) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (3) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (4) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (5) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Sana class action, go to https://rosenlegal.com/submit-form/?case_id=37267 or https://rosenlegal.com/submit-form/?case_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/sana-deadline-sana-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-sana-biotechnology-inc-securities-fraud-lawsuit-302457899.html
SOURCE THE ROSEN LAW FIRM, P. A.
PR Newswire
NEW YORK
, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating the proposed buyout of TaskUs, Inc. (Nasdaq: TASK) by the company’s three largest shareholders: private equity firm Blackstone and co-founders Bryce Maddock and Jaspar Weir.
For a free consultation, please visit https://julieholleman.com/taskus-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at [email protected].
TaskUs is a leading provider of outsourced digital services and next-generation customer experience to the world’s most innovative companies. The company has a bright future, and Wall Street analysts have established one-year stock price targets averaging $18.50 per share, with a high target of $22 per share.
On May 9, 2025, however, TaskUs announced that it would be sold to the buyer group, which already controls a majority of the company’s voting power. Blackstone, Maddock, and Weir will buy out public shareholders for just $16.50 per share.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars in prior cases, is pursuing potential legal claims based on the apparent unfairness of the deal. The firm is concerned about conflicts arising from the fact that key insiders are continuing on with the company while public TaskUs shareholders are being cashed out for a price that is well below the company’s true value.
Please visit https://julieholleman.com/taskus-inc/, or contact partner Scott Holleman at (929) 415-1020 or [email protected] for more information.
FIRM INFORMATION
Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm’s attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit www.julieholleman.com. This notice may constitute attorney advertising.
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/task-alert-taskus-shareholders-interesting-in-pursuing-potential-claims-should-contact-shareholder-rights-firm-regarding-proposed-buyout-302458279.html
SOURCE Julie & Holleman LLP
PR Newswire
NEW YORK
, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating potential claims against Ibotta, Inc. (NYSE: IBTA) and its executives for recent losses suffered by the company’s stockholders.
For a free consultation, please visit https://julieholleman.com/ibotta-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at [email protected].
According to a complaint recently filed in federal court, Ibotta and its executives misled investors regarding risks associated with The Kroger Co., one of the company’s largest customers. In addition, after going public at an IPO price of $88 per share, Ibotta’s stock has dropped sharply, costing investors huge sums of money.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars in prior cases, is investigating legal claims against Ibotta, its executives, and potentially also the company’s board of directors.
FIRM INFORMATION
Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm’s attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit www.julieholleman.com. This notice may constitute attorney advertising.
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ibotta-shareholders-should-contact-shareholder-rights-firm-regarding-potential-legal-claims-302458277.html
SOURCE Julie & Holleman LLP
PR Newswire
NEW YORK
, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating the acquisition of Skechers U.S.A., Inc. (NYSE: SKX) by global investment firm 3G Capital. The law firm has already uncovered conflicts of interest and believes the deal price is too low.
For a free consultation, please visit https://julieholleman.com/skechers-usa-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at [email protected].
Skechers is a footwear company controlled by the Greenberg family, which includes company founder, CEO, and chairman Robert Greenberg and his son, Michael Greenberg, who serves as president and as a member of the board of directors. The Greenbergs collectively own more than 60% of the company’s stock and corresponding voting power.
On May 5, 2025, Skechers announced that it would be sold to 3G Capital and become a private company. Under the deal, Skechers stockholders may receive either $63 per share in cash, or $57 per share in cash plus a share in the post-close, private entity. However, the post-close units may not be traded without 3G’s consent and are subject to numerous other restrictions.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars in prior cases, is pursuing potential legal claims based on the apparent unfairness of the deal. The firm is concerned about conflicts of interest of the Greenbergs, who have committed to participating in the company after the deal is completed. The firm is also concerned that the upfront cash deal price ($63 per share or $57 per share) is far below Skechers’ true value.
Please visit https://julieholleman.com/skechers-usa-inc/, or contact partner Scott Holleman at (929) 415-1020 or [email protected] for more information.
FIRM INFORMATION
Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm’s attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit www.julieholleman.com. This notice may constitute attorney advertising.
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/skechers-shareholders-unhappy-with-merger-should-contact-shareholder-rights-firm-regarding-potential-legal-claims-302458278.html
SOURCE Julie & Holleman LLP
PR Newswire
NEW YORK
, May 17, 2025 /PRNewswire/ — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) and its executives for recent losses suffered by the company’s stockholders.
For a free consultation, please visit https://julieholleman.com/iovance-biotherapeutics-inc/. You may also contact partner Scott Holleman at (929) 415-1020 or by email at [email protected].
According to a complaint recently filed in federal court, Iovance and its executives misled investors by exaggerating the company’s financial prospects and downplaying risk factors affecting the company’s growth potential. Among other things, the complaint alleges that the company concealed that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars in prior cases, is investigating legal claims against Iovance, its executives, and potentially also the company’s board of directors.
FIRM INFORMATION
Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm’s attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit www.julieholleman.com. This notice may constitute attorney advertising.
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/iovance-shareholders-should-contact-shareholder-rights-firm-regarding-potential-legal-claims-302458275.html
SOURCE Julie & Holleman LLP
NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company’s senior executives for potential violations of the federal securities laws.
If you invested in Compass you are encouraged to obtain additional information by visiting
https://www.bfalaw.com/cases-investigations/compass-diversified-holdings
.
Investors have until July 8, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Compass securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981.
Why was Compass Sued for Securities Fraud?
Compass is a statutory trust that acquires and manages a group of small and middle-market businesses. This includes Lugano Holdings, Inc., a designer, manufacturer, and marketer of high-end jewelry. The complaint alleges that the Company’s fiscal 2024 financial statements contained material misstatements relating to unrecorded financing arrangements and irregularities identified in sales, cost of sales, inventory, and accounts receivable recorded by Lugano.
The Stock Declines as the Truth is Revealed
On May 7, 2025, after the market closed, Compass announced that investors should not rely on its fiscal 2024 financial statements amid an ongoing internal investigation, led by outside counsel and a forensic accounting firm, into Lugano. The Company stated that it has “preliminarily identified irregularities in Lugano’s non-CODI financing, accounting, and inventory practices.” The Company also announced that it intended to delay the filing of its Q1 2025 financial results, and that Lugano’s founder and CEO, Moti Ferder, resigned from his positions at Lugano and will not receive any severance compensation. On this news, the price of Compass stock declined roughly 62%, from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025.
Click here if you suffered losses:
https://www.bfalaw.com/cases-investigations/compass-diversified-holdings
What Can You Do?
If you invested in Compass you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/compass-diversified-holdings
Or contact:
Ross Shikowitz
[email protected]
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/compass-diversified-holdings
Attorney advertising. Past results do not guarantee future outcomes.
NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Resources, Inc. (NYSE: CIVI) and certain of the Company’s senior executives for potential violations of the federal securities laws.
If you invested in Civitas you are encouraged to obtain additional information by visiting
https://www.bfalaw.com/cases-investigations/civitas-resources-inc
.
Investors have until July 1, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Civitas securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned Lin v. Civitas Resources., et al., No. 25-cv-03791.
Why was Civitas Sued for Securities Fraud?
Civitas is an oil and gas exploration and production company with its key assets located in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico. The complaint alleges that Civitas stated that both basins had “enhanced recovery potential” and that it had “driven production ahead of plans,” while touting “enhanced margins through reduced operating costs” and insisting that “costs are below expectations.”
In truth, the Company’s oil production peaked in 2024, and increasing production would require Civitas to spend significant capital to acquire additional land, driving up costs.
The Stock Declines as the Truth is Revealed
On February 24, 2025, Civitas announced disappointing Q4 and full year 2024 results, and reduced its oil production guidance. The Company explained that oil production had peaked and it would need to spend hundreds of millions of dollars to acquire thousands of acres of new land to produce more oil. Civitas also announced that it was implementing a 10% reduction in its workforce to “solidify the Company’s low-cost structure.” On the same day, Civitas announced the immediate firings of its Chief Operating Officer and Chief Transformation Officer. On this news, the price of Civitas stock declined more than 18%, from a closing price of $49.30 per share on February 24, 2025, to $40.35 per share on February 25, 2025.
Click here if you suffered losses:
https://www.bfalaw.com/cases-investigations/civitas-resources-inc
.
What Can You Do?
If you invested in Civitas you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/civitas-resources-inc
Or contact:
Ross Shikowitz
[email protected]
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/civitas-resources-inc
Attorney advertising. Past results do not guarantee future outcomes.
NEW YORK, May 17, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws.
If you invested in Elevance you are encouraged to obtain additional information by visiting
https://www.bfalaw.com/cases-investigations/elevance-health-inc
.
Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock. The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092.
Why was Elevance Sued for Securities Fraud?
Elevance provides health insurance plans. This includes contracting with states to administer Medicaid benefits. States routinely review Medicaid eligibility, but during COVID, the federal government paused this process. The pause ended in 2023, and states resumed redetermining Medicaid eligibility.
During the relevant period, Elevance represented that it was closely monitoring the cost trends associated with the redetermination process and that the rates Elevance was negotiating were sufficient to address the risk profiles of those patients staying on Medicaid.
As alleged, in truth, the redeterminations caused a significant increase in the acuity and utilization of Elevance’s Medicaid members. What’s more, the shift occurred to a degree that was not reflected in Elevance’s rate negotiations or in its financial guidance for 2024.
The Stock Declines as the Truth is Revealed
On July 17, 2024, Elevance stated that it was now “expecting second-half utilization to increase in Medicaid” and that it was “seeing signs of increased utilization across the broader Medicaid population.” On this news, the price of Elevance stock declined $32.21 per share, or nearly 6%, from $553.14 per share on July 16, 2024, to $520.93 per share on July 17, 2024.
Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share (“EPS”) expectations by $1.33, or 13.7%, “due to elevated medical costs in [its] Medicaid business.” On this news, the price of Elevance stock declined $52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to $444.35 per share on October 17, 2024.
Click here if you suffered losses:
https://www.bfalaw.com/cases-investigations/elevance-health-inc
.
What Can You Do?
If you invested in Elevance you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/elevance-health-inc
Or contact:
Ross Shikowitz
[email protected]
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/elevance-health-inc
Attorney advertising. Past results do not guarantee future outcomes.
